Avelumab in newly diagnosed glioblastoma

BACKGROUND: Glioblastoma (GBM) is known to use both local and systemic immunosuppressive strategies. One such strategy is the expression of the immune checkpoint protein programmed cell death ligand-1 (PD-L1) by both tumor cells and tumor-associated immune cells. Recent phase III trials using IgG4 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacques, Francois H, Nicholas, Garth, Lorimer, Ian A J, Sikati Foko, Victorine, Prevost, Jasmine, Dumais, Nathalie, Milne, Katy, Nelson, Brad H, Woulfe, John, Jansen, Gerard, Apedaile, B Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482788/
https://www.ncbi.nlm.nih.gov/pubmed/34604752
http://dx.doi.org/10.1093/noajnl/vdab118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482788/
https://www.ncbi.nlm.nih.gov/pubmed/34604752
http://dx.doi.org/10.1093/noajnl/vdab118

Ejemplares similares